MarketCap
IDEAYA Biosciences IDYA
$ 31.72
-1.34%
Facebook
X
Telegram
IDEAYA Biosciences EV/EBITDA Ratio | IDYA
Annual EV/EBITDA Ratio IDEAYA Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.2 | -5.18 | -18.1 | -11.9 | -11.8 | -13.6 | -1.98 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.98 | -18.1 | -11.4 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Wave Life Sciences Ltd.
WVE
|
-9.94 | $ 3.41 | -2.01 % | $ 575 M |  Singapore |
 |
Molecular Templates
MTEM
|
-7.78 | - | -23.43 % | $ 495 K |  USA |
 |
Exicure
XCUR
|
-8.87 | $ 1.08 | 21.31 % | $ 6.8 M | USA |
 |
Immunome
IMNM
|
-5.79 | $ 18.65 | -3.67 % | $ 1.63 B | USA |
 |
Xeris Pharmaceuticals
XERS
|
46.8 | $ 15.81 | -0.35 % | $ 2.54 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
-0.771 | $ 3.24 | -2.7 % | $ 137 M | USA |
 |
Xencor
XNCR
|
-6.45 | $ 39.42 | 2.16 % | $ 2.93 B | USA |
 |
INmune Bio
INMB
|
-0.26 | $ 1.09 | -3.54 % | $ 27 M | USA |
 |
Insmed Incorporated
INSM
|
-26.4 | $ 119.55 | 2.97 % | $ 23.8 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-76.2 | $ 28.02 | -9.63 % | $ 4.48 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-2.54 | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
InflaRx N.V.
IFRX
|
-1.93 | $ 1.21 | -7.63 % | $ 81.4 M |  Germany |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-396 | $ 1.78 | 16.33 % | $ 1.2 B |  Israel |
 |
22nd Century Group
XXII
|
-0.173 | $ 1.46 | -10.43 % | $ 269 K | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
-1.16 | $ 4.82 | 2.99 % | $ 780 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-23.5 | $ 245.39 | 0.76 % | $ 15 B |  Irlanda |
 |
Zai Lab Limited
ZLAB
|
-99.8 | $ 26.56 | -1.12 % | $ 29.1 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
-1.5 | $ 1.8 | 3.16 % | $ 129 M | USA |
 |
CohBar
CWBR
|
-0.0334 | - | -15.44 % | $ 2.2 M | USA |
 |
Zoetis
ZTS
|
135 | $ 82.45 | 0.15 % | $ 36.6 B | USA |
 |
NeuBase Therapeutics
NBSE
|
0.988 | - | -1.56 % | $ 12.3 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-5.93 | - | - | $ 2.18 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-8.74 | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
-0.314 | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
-1.23 | $ 0.85 | -5.53 % | $ 17.5 M | USA |
 |
scPharmaceuticals
SCPH
|
-0.286 | - | - | $ 218 M | USA |
 |
Johnson & Johnson
JNJ
|
13.1 | $ 281.13 | -0.35 % | $ 677 B | USA |
 |
Kala Pharmaceuticals
KALA
|
0.0884 | $ 0.17 | -2.59 % | $ 1.39 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-0.978 | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
0.12 | - | 3.77 % | $ 22.4 M | USA |
 |
Global Blood Therapeutics
GBT
|
-6.65 | - | - | $ 4.62 B | USA |
 |
Longeveron
LGVN
|
-750 | $ 2.77 | 37.81 % | $ 48.7 B | USA |
 |
Inozyme Pharma
INZY
|
-0.428 | - | - | $ 207 M | USA |
 |
MediWound Ltd.
MDWD
|
-13.1 | $ 14.05 | -0.21 % | $ 382 M | Israel |
 |
Idera Pharmaceuticals
IDRA
|
-1.86 | - | -23.04 % | $ 26.6 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
2.69 K | $ 94.4 | 1.31 % | $ 4.74 B | USA |
 |
NanoString Technologies
NSTG
|
-4.54 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
-0.883 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
-0.959 | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-0.931 | - | - | $ 59.7 M | USA |
 |
Sierra Oncology
SRRA
|
-2.09 | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-0.867 | $ 1.03 | -6.33 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-2.05 | $ 4.24 | -3.97 % | $ 346 M | USA |
 |
Nektar Therapeutics
NKTR
|
-9.13 | $ 37.82 | -0.01 % | $ 638 M | USA |
 |
Vaccinex
VCNX
|
-0.372 | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-6.09 | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-10.5 | - | - | $ 3.67 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-12.5 | $ 1.05 | -3.24 % | $ 242 M | USA |
 |
Jounce Therapeutics
JNCE
|
1.47 | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
-285 | - | - | $ 69.7 B |  Britain |